Biofunctionalization of Biomaterials for Accelerated in Situ Endothelialization: A Review

Centre of Nanotechnology, Biomaterials and Tissue Engineering, UCL Division of Surgery & Interventional Science, University College London, London, United Kingdom.
Biomacromolecules (Impact Factor: 5.79). 11/2008; 9(11):2969-79. DOI: 10.1021/bm800681k
Source: PubMed

ABSTRACT The higher patency rates of cardiovascular implants, including vascular bypass grafts, stents, and heart valves are related to their ability to inhibit thrombosis, intimal hyperplasia, and calcification. In native tissue, the endothelium plays a major role in inhibiting these processes. Various bioengineering research strategies thereby aspire to induce endothelialization of graft surfaces either prior to implantation or by accelerating in situ graft endothelialization. This article reviews potential bioresponsive molecular components that can be incorporated into (and/or released from) biomaterial surfaces to obtain accelerated in situ endothelialization of vascular grafts. These molecules could promote in situ endothelialization by the mobilization of endothelial progenitor cells (EPC) from the bone marrow, encouraging cell-specific adhesion (endothelial cells (EC) and/or EPC) to the graft and, once attached, by controlling the proliferation and differentiation of these cells. EC and EPC interactions with the extracellular matrix continue to be a principal source of inspiration for material biofunctionalization, and therefore, the latest developments in understanding these interactions will be discussed.


Available from: Gavin Jell, Jan 31, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background There is a considerable clinical need for a sufficient prosthetic small-diameter substitute which can compete with autologous vessels. Currently used synthetic materials have a poor performance due to high thrombogeneicity and development of intimal hyperplasia. Tissue engineering is an interesting alternative approach for vascular graft fabrication. Methods We briefly overviewed the development of tissue-engineered vascular substitutes including endothelialized biohybrid grafts, collagen and fibrin-based scaffolds, decellularized scaffolds, cell self-assembly approaches, and biodegradable constructs based on synthetic polymers. Results Significant advances have been made over the past decades in the development of tissue-engineered conduits. Biomechanical weakness, one of the major limitations of biologically based grafts has been resolved and two tissue-engineered grafts are currently under further investigation for clinical application. Conclusions Vascular tissue engineering is a promising approach to overcome the limitations of current therapies in small-diameter vascular replacement.
    European Surgery 08/2013; 45(4):187-193. DOI:10.1007/s10353-013-0224-x · 0.26 Impact Factor
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: With the development of modern medical technology, the clinical range of biomaterial applications have gradually expanded. However, bioactivity on the surface of biomaterials may be reduced and induce thrombus formation that will not only cause serious dysfunction of the biological materials, but can also affect the host. Modification of these biological materials can thus help to retain the biological activity on the surface of the material and inhibit thrombus formation, which underlines the importance of their clinical application. The current review will address the modification of biomaterials and inhibition of thrombosis on the surface of biomaterials.
    12/2013; 873:635-641. DOI:10.4028/